Compare Delta Air Lines, Inc. (DAL) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Delta Air Lines, Inc. trades at $82.59 (market cap $54.56B), while Iovance Biotherapeutics Inc. Common Stock trades at $13.42 (market cap $5.85B). The key difference: Delta Air Lines, Inc. is far larger — about 9.3× Iovance Biotherapeutics Inc. Common Stock's market cap, and Delta Air Lines, Inc. pays a 1.04% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| DAL | IOVA | |
|---|---|---|
Market Cap | $54.56B | $5.85B |
Volume | 6,532,736 | 14,517,176 |
Sector | Industrials | Health |
52-Week High | $93.66 | $14.82 |
52-Week Low | $55.65 | $1.81 |
Typical Hold Time | 97 Days | 0 Days |
Enterprise Value | $69.88B | $5.78B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.14, down 1.82% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. DAL maintains solid profitability with 5.78% net margin and 20.12% ROE, while trading at attractive valuations with P/E of 13.76 and P/S of 0.8. Recent news highlights competitive pressures from United and American's customer poaching efforts and Delta's decision to use Amazon's internet service over Starlink.
DAL presents a compelling value opportunity with strong analyst support (82% buy ratings) and 26% upside to consensus target of $103.36. However, near-term risks include fuel cost volatility, competitive threats to premium customers, and execution challenges. The improving cash flow trend with $1.08B net cash generation in 2025 supports dividend sustainability and operational flexibility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
